Literature DB >> 36094655

Nanomaterials for antigen-specific immune tolerance therapy.

Jinwon Park1, Yina Wu1, Qiaoyun Li1, Jaehyun Choi1, Hyemin Ju1, Yu Cai2, Jaiwoo Lee1, Yu-Kyoung Oh3.   

Abstract

Impairment of immune tolerance might cause autologous tissue damage or overactive immune response against non-pathogenic molecules. Although autoimmune disease and allergy have complicated pathologies, the current strategies have mainly focused on symptom amelioration or systemic immunosuppression which can lead to fatal adverse events. The induction of antigen-specific immune tolerance may provide therapeutic benefits to autoimmune disease and allergic response, while reducing nonspecific immune adverse responses. Diverse nanomaterials have been studied to induce antigen-specific immune tolerance therapy. This review will cover the immunological background of antigen-specific tolerance, clinical importance of antigen-specific immune tolerance, and nanomaterials designed for autoimmune and allergic diseases. As nanomaterials for modulating immune tolerances, lipid-based nanoparticles, polymeric nanoparticles, and biological carriers have been covered. Strategies to provide antigen-specific immune tolerance have been addressed. Finally, current challenges and perspectives of nanomaterials for antigen-specific immune tolerance therapy will be discussed.
© 2022. Controlled Release Society.

Entities:  

Keywords:  Allergic disease; Autoimmune disease; Nanomaterials; Nanoparticles; Tolerogenic vaccine

Year:  2022        PMID: 36094655     DOI: 10.1007/s13346-022-01233-3

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   5.671


  145 in total

Review 1.  The multiple pathways to autoimmunity.

Authors:  Argyrios N Theofilopoulos; Dwight H Kono; Roberto Baccala
Journal:  Nat Immunol       Date:  2017-06-20       Impact factor: 25.606

Review 2.  Immunological mechanisms of allergen-specific immunotherapy.

Authors:  Mark Larché; Cezmi A Akdis; Rudolf Valenta
Journal:  Nat Rev Immunol       Date:  2006-10       Impact factor: 53.106

3.  No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

Authors:  P Pozzilli; D Pitocco; N Visalli; M G Cavallo; R Buzzetti; A Crinò; S Spera; C Suraci; G Multari; M Cervoni; M L Manca Bitti; M C Matteoli; G Marietti; F Ferrazzoli; M R Cassone Faldetta; C Giordano; M Sbriglia; E Sarugeri; G Ghirlanda
Journal:  Diabetologia       Date:  2000-08       Impact factor: 10.122

4.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.

Authors:  A G Fraser; T R Orchard; D P Jewell
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 5.  Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.

Authors:  Simon Faissner; Jason R Plemel; Ralf Gold; V Wee Yong
Journal:  Nat Rev Drug Discov       Date:  2019-08-09       Impact factor: 84.694

Review 6.  Advances in mechanisms of allergy and clinical immunology in 2012.

Authors:  Bruce S Bochner; Marc E Rothenberg; Joshua A Boyce; Fred Finkelman
Journal:  J Allergy Clin Immunol       Date:  2013-01-23       Impact factor: 10.793

Review 7.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

Review 8.  The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines.

Authors:  Robin L Thurmond; Erwin W Gelfand; Paul J Dunford
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

Review 9.  Discovering susceptibility genes for asthma and allergy.

Authors:  Donata Vercelli
Journal:  Nat Rev Immunol       Date:  2008-03       Impact factor: 53.106

Review 10.  A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool?

Authors:  Simona Ronchetti; Emira Ayroldi; Erika Ricci; Marco Gentili; Graziella Migliorati; Carlo Riccardi
Journal:  Front Immunol       Date:  2021-01-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.